# A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy.

> **NCT03971110** · PHASE4 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 9 (actual)

## Conditions studied

- Advanced Prostate Cancer

## Interventions

- **DRUG:** Zoladex and Casodex

## Key facts

- **NCT ID:** NCT03971110
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-28
- **Primary completion:** 2022-11-09
- **Final completion:** 2022-11-09
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Due to the limited potential patients pool, the enrollment goal could not be achieved. After review and communication, the decision to teminate study was made.
- **Last updated:** 2022-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03971110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03971110, "A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03971110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*